Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Merck Closes SciBrunch License With $2.13B Potential

28 September 2026 · By · Wire by Fusion42

Published

28 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at stocktitan.net →

◆ Verified

Fusion42 · 28 September 2026 · Fusion42 review

Merck has entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D inhibitor, with potential payments up to $2.13 billion based on milestone achievements across multiple cancer indications.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a clear signal that big pharma is doubling down on KRAS-targeted cancer drugs with multi-billion dollar license deals. This opens doors to partner with Merck or similar firms as they seek novel therapies with strong preclinical data.

◆ Coverage

1 source · 28 Sep 2026

◆ Related on Wire

◆ Topics

Biotechoncologydrug-developmentkrass-inhibitorlicense-dealbiotech-partnership